Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.

Despite chemotherapy, median survival of patients with advanced pancreatic cancer (APC) remains poor. Gemcitabine (GEM) remains standard treatment. Numerous phase II studies have suggested that combination therapies may improve response rates.